The mission of PharmaEssentia is to provide comprehensive R&D, innovative and breakthrough drugs to patients in need to solve their suffering and improve their lives and health. Upholding our sense of purpose, after more than 10 years of efforts to develop our innovative drug, the Ropeginterferon alfa-2b (P1101), we finally launched it on the EU market in 2019. The Company upholds its original purpose and provides drugs to patients with Polycythemia Vera (PV) at a reasonable and affordable price considering the overall local economic conditions and the financial ability of patients. In the next 10 years, we will unremittingly devote ourselves to the development of new drugs. Moreover, through the access plan, we will continue to ensure the “accessibility” of new drugs for patients around the world to meet their disease treatment needs and reduce the accessibility gap around the world; the “affordability” of new drugs to help patients obtain medicines at reasonable, fair and affordable prices; and the “availability” of new drugs to promote easier access to the drugs needed by patients in economically disadvantaged countries. Starting from our core capabilities, we create sustainable shared value with stakeholders, and promote the health and well-being of all mankind.
The popularization of medicines often has positive significant benefits for disease control. Access to Medicine is crucial to maintaining the public health of mankind and the continuation of life, providing patients with reasonable and affordable drug prices and a stable source of supply, while ensuring accessibility of drugs among patients. This plays an important role in the rights to health worldwide. The original purpose of the Company is to use our innovative drugs to solve the suffering of patients and promote the health and well-being of all mankind. This mission and responsibility is also in line with the UN SDG 3 released in September 2015 and officially implemented since 2016. Regarding access to medicine, we take the enhancement of “accessibility,” “affordability” and “availability” as our core values. In addition, we follow the framework of the 2018 Access to Medicine Index to formulate strategies and guidelines to reduce the gap between access to medicine around the world, so patients can obtain the drugs they need in a reasonable, affordable, correct and easy way, so as to fulfill our original purpose and philosophy of the establishment of the Company.
Our mission is to “Develop innovative drugs to treat patients and meet healthcare needs and life safety”. The Company has conducted more than 20 clinical trials around the world and focuses on the clinical trials and development of new drugs in four major disease areas. For the Company, cooperation with local academic institutions enables us to get a better grasp and deeper understanding of the medical needs of the public health system in various regions. Based on the long-accumulated knowledge and insights of related diseases of external academic institutions, as well as our ability in the latest and most cutting-edge technology and skills, we can jointly implement the medicine access plans required by different diseases in different regions. Compassionate Use is the use of a new, under-trial, unapproved drug, which has been scientifically developed, in the treatment of patients in critical or serious condition who lack any alternative medicines, or have no response after all available medications, experience relapse, or have contraindications. Taking Taiwan as an example, starting in 2017, with the application submitted by the physicians and patients and approval from TFDA, the Ropeginterferon alfa-2b (P1101), which was then a new drug under clinical trial phases, served as the Compassionate Use drug for the treatment of Primary Myelofibrosis (PMF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET).
At present, the Company has obtained 75 patents worldwide, covering 68 countries around the world. PharmaEssentia promises that, in addition to the global prevalence of the indications of the new drugs, we take special consideration for the patients’ access to medicine in the least developed countries and low income countries to ensure that the demand for drugs in non-developed countries can be fulfilled as in developed countries. In case of weighing between utilization of patents and humanitarian aid, PharmaEssentia will first prioritize the patients’ access to medicine, so that patients in need can obtain the required drugs at an affordable price and in a convenient manner. We will also regularly draw up intellectual property management plans that are integrated with our operations, and proactively disclose our patent policies, application, and implementation status.
With patents, we not only actively out-license new drug technologies to academic research institutions and partners for disease treatment related research, but also actively cooperate with large foreign pharmaceutical companies to in-license patents and technologies. This not only promotes the sharing of intellectual property rights, but also demonstrates our philosophy in sustainable management in accountability, integrity, and transparent communication. And this also provides the public with better access to new inventions, in aim to promote public health to achieve social progress and the welfare of the people.
The accessibility of medicines depends on the stable operation and supply of related companies in the value chain. The accessibility of medicine will be severely affected if the pharmaceutical biotechnology companies are unwilling to sell drugs in the local market, the price is not affordable to patients, or the supply chain is disrupted. PharmaEssentia is actively applying for drug licenses in global markets. With safe drugs, stable supply chain, reasonable pricing, and correct health education the Company is committed to meet the needs of patients for safe medication and to promote PharmaEssentia’s corporate sustainability.
The patients’ rights are the priority pricing criteria of PharmaEssentia’s medicine. As only through fair, reasonable and affordable prices can all patients in need be taken care of. However, in addition to considering the financial ability of patients, we also take into consideration the overall factors covering the R&D costs invested, the number of patients during the patent term, competitive products and expected profits, third-party insurance companies, or the competent authorities of various countries when setting drug prices. At present, the Company’s pricing strategy is to formulate reasonable and fair prices based on the affordability of medical expenses in various countries with reference to the WHO Guideline on Country Pharmaceutical Pricing Policies issued by the World Health Organization (WHO), and make necessary adjustments according to economic development of the target country and pharmaceutical costs. For example, the first criterion for drawing up our Tiered Pricing model is the level of development in each sales area. The second criterion is whether national health insurance is imposed in that sales area. For example, in Taiwan, South Korea, Japan, UK, and Australia, the price of medicines is mainly determined by the national insurance unit. As for other areas, we take into consideration the gross domestic product (GDP) of each country and the affordability of medical expenses for private health insurance units. The third criterion is the market price of drugs for similar diseases.
In 2020, along obtaining the drug permit license for the Ropeginterferon alfa-2b (P1101) issued by the TFDA, PharmaEssentia will actively expand the Patient Assistant Program. For patients with myeloproliferative neoplasms (MPN), we will provide them with self-funded subsidies, plans, various health education platforms, materials and tools. We will also follow the pharmaceutical marketing ethics regulations of the International Research-Based Pharmaceutical Manufacturers Association (IRPMA) of the R.O.C, comply with ethical regulations and relevant drug and medical regulations, and ensure proper interaction with relevant organizations and associations.
“Remember the original purpose” is the belief that PharmaEssentia upholds since its establishment 17 years ago. As a new drug company, our “original purpose” is to develop new drugs to treat patients and to become a leading new biopharmaceutical company among the Chinese community worldwide. With our core capabilities, we actively participate in experience sharing activities with Taiwan’s local companies in the same industry, government units, and value chain partners. We also actively participate in various types of international and domestic seminars to discuss on concerned issues regarding related diseases. With the Company’s own experience in the establishment of a complete and excellent quality system, we assisted our contract research organization partner, the Agricultural Technology Research Institute, to obtain the EU certification for GMP laboratory. It has successfully obtained the certification and become the first biosafety testing laboratory in Taiwan.
|2019 CSR Report|